未知生产厂商
AK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).
AK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).
AK119 binds to, and inhibits, human CD73 with high affinity. It was seen to result in CD73 internalization and promotion of IgG production from B cells in studies. This drug is currently being investigated as immunotherapy for COVID-19.
